Use of trade names and commercial sources is for identification only and does not imply endorsement by the U. Department of Health and Human Services.
CDC is not responsible for the content of pages found at these sites. This conversion might result in character translation or format errors in the HTML version. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.
Contact GPO for current prices. Skip directly to search Skip directly to A to Z list Skip directly to site content. Protecting People. Search The CDC. Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. This conversion might result in character translation or format errors in the HTML version. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.
Contact GPO for current prices. Skip directly to search Skip directly to A to Z list Skip directly to site content. Protecting People. The most common local and systemic adverse reactions to a primary dose of Menactra include pain, redness, and swelling at the injection site and appetite loss all age groups ; induration at the injection site and diarrhea all age groups except infants ; irritability and drowsiness infants and children ; abnormal crying, vomiting, and fever infants ; headache, fatigue, malaise, and arthralgia adolescents and adults.
Overall rates of solicited injection site reactions and solicited systemic reactions following a booster dose of Menactra were similar to those observed in adolescents and adults after a single Menactra dose.
In the US, Sanofi Pasteur has been a leader in this fight for more than 40 years. A total of participants were enrolled; of these, met criteria for inclusion in the per-protocol population for the immunogenicity analysis.
0コメント